The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
The great AI buildout shows no sign of slowing
By Akash Sriram (Reuters) -A momentous week in the technology sector made it clear there is no sign the boom…
Former Fed Governor Kugler’s exit came amid forbidden trading activity
By Michael S. Derby NEW YORK (Reuters) -Former Federal Reserve Governor Adriana Kugler, who abruptly resigned this summer, had multiple…
Amundi’s Mortier worried about Fed independence, cautious on megacap stocks
By Yoruk Bahceli LONDON (Reuters) -Damage to the independence of the U.S. Federal Reserve remains a risk going into 2026,…